Member Info for doze

£2.7m trade at 3.30.

http://www.eservglobal.com/system/files/20131107_eSG_HomeSend_MLhuillier.pdf Live in January 2014 Rising nicely before and after this release, shame about hurricane Haiyan, the Phillipino is well aware of international communities and know how to appeal for help as so many work abroad.

Hi, I think that big trade shows this company has a future, regular income from a small % of a gas bill (with inflationary adjustments upwards easily added on) for smart meters which are mandatory for industrial and commercial (I&C) buildings with many firms missing the deadline for installation. As leading player EAS you would think, would grab more of the market. I bought in at 3.46 on Monday. Figures are good because if meters have a 20 year life but capital cost is accounted for on installation then, well, just imagine- eventually a lot of income and no costs!

348,744 trade surely a buy?

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11770697 I can't see much wrong with it

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11770698

http://www.proactiveinvestors.co.uk/genera/files/companies/tissue_reggenre.pdf

Decided to do some research after your post! Family holdings total over 19% ! http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11760346

http://uk.finance.yahoo.com/news/thursday-tips-round-acs-bp-083500680.html LONDON (ShareCast) - Advanced Computer Software's Chief Executive Officer, VinMurria, is on the war path. After a big investor forced her into a sale of Computer Software Holding (CSH), her previous company at which she managed to engineer a growth spurt, she vowed never to make the same mistake. Now, as Chief of Advanced Computer Software, she has managed to purchase CSH, and ACS (Madrid: ACS.MC - news) has been going from strength to strength. First (Other OTC: FSTC - news) half revenue growth was up 74 per cent to 99m pounds and pre-tax profits higher by seven per cent, and it wasn't all down to non-organic growth. Cash generation remains significant - at £18.7m at the interim stage - and the company now has a war chest of £40m. The shares are trading at a modest 14 times projected earnings and could be due a re-rating. Take a punt, says The Times' Tempus.

Tom Bulford when he was RHPS editor, it is still in the portfolio.

Tipped 6/13 @ 14.125

Well spotted re £1bn market, rns seems to have generated a lot of trades

http://www.investegate.co.uk/tissue-regenix-group/trx/publication-of-dermapure-uk-trial-results/201310210700099186Q/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Tissue%20Regenix%20Group%20Alert The clinical paper states that 1-in-100 people in the UK will suffer from a leg ulcer during their lifetime, with treatment of these chronic wounds taking 1% of the country's annual healthcare budget.

Now 2.99% so potential seller now without having to report so maybe depress the SP for a while.

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11743697

http://www.brrmedia.co.uk/event/112676/julie-simmonds-analyst-canaccord-genuity-karl-keegan-group-director-of-corporate-development-vectura-ewan-phillips-ceo-deltex-medical-christine-soden-cfo-electrical-geodesics?popup=true&wl=730 14.40-17.30

LOL

Having seen the business develop over the last four years under the current management team to its position today, Transense has now reached the stage where it is seeing marked improvement in revenue and in its prospects - indeed new business opportunities are building faster than at any previous point in its history. With the Company's SAW solutions finding resonance with an international range of distributors, partners and key customers, and following almost 6 years in the role, I feel that now is the appropriate time to relinquish the role of Chairman. http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11738522

Nice rnss eh langy http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11735789 The US$6 million milestone was triggered by a compound, the Candidate, discovered by HMP in collaboration with Janssen meeting certain development candidate criteria pursuant to the Agreement. Upon achievement of specific clinical development and approval milestones, HMP may potentially receive up to an additional US$90.5 million and is entitled to royalties on worldwide sales upon commercialisation of a product by Janssen. from yoursChristian Hogg, Chief Executive Officer of Chi-Med said: "Our belief is that Fruquintinib has potential activity against multiple tumour types with high incidence rates and may benefit patients with significant unmet medical needs in China. The collaboration with Lilly will allow for Fruquintinib to be developed across various tumour types in China and at a far greater speed than if we went alone." "We are excited to collaborate with Hutchison MediPharma in the development of this potential new cancer therapy," said Jacques Tapiero, Lilly Senior Vice President and President of Emerging Markets. "In Lilly's emerging markets business, we are focused on providing patients with innovative medicines from our own pipeline and through collaborations with respected science-based companies such as HMP. Together, we are committed to help meet the medical needs of oncology patients in China."

Yes, I agree with your thoughts, it points to a fairly amicable transfer of rights to GDG without it costing either side anything, just an aligning behind the rightful licence holder.